- eXmoor Pharma and the Translational Research Office at University College London have formed a strategic collaboration to accelerate the translation of academic cell and gene therapy research into clinical application.
- The partnership combines UCL’s translational expertise with eXmoor’s consultancy, development and GMP manufacturing capabilities.
eXmoor Pharma has entered a strategic collaboration with the Translational Research Office (TRO) at University College London (UCL) to accelerate the development of novel cell and gene therapies from academic research into clinical use. The partnership aims to create earlier and more efficient engagement between UCL innovators and eXmoor’s multidisciplinary teams.
The two organisations will work together to reduce the risk, cost and complexity associated with technology development. The collaboration combines the TRO’s translational expertise with eXmoor’s consultancy, development and Good Manufacturing Practice capabilities, supporting faster progress towards clinical trial readiness. The partnership also provides structured access to CMC consulting, regulatory strategy support, laboratory capacity, and GMP manufacturing for early clinical studies.
Academic teams at UCL will gain early access to process and analytical development expertise, cross-modality insight across viral vectors, autologous and allogeneic cell therapies, and RNA technologies. This engagement includes opportunities for grant input, regular consultancy clinics and joint events designed to bridge the gap between academic innovation and GMP-ready development.
eXmoor will work directly with UCL’s translational researchers to stay aligned with emerging technologies and evolving CGT modalities. This early collaboration is intended to support scalable, practical solutions with clinical and commercial potential in the CGT sector, including areas relevant to CDMO and contract manufacturing activities.
“The strength of the UK’s academic science has always been clear but getting groundbreaking therapies from the lab to patients requires a collaborative approach. This partnership with UCL TRO reflects our shared belief that supporting translational research with practical, GMP-ready solutions is the key to unlocking meaningful outcomes for patients.”
Angela Osborne, Founder & Executive Chair of eXmoor Pharma
Pamela Tranter, Head of the Translational Research Group at UCL Translational Research Office, said the partnership would help connect researchers with industry expertise to develop practical and scalable plans to advance therapeutic potential.
